Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Genentech
|
| gptkbp:activities |
Ig E binding inhibition
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:class |
immunomodulator
|
| gptkbp:clinical_trial |
gptkb:EXCELS_study
Phase III long-term management Omalizumab for Chronic Urticaria study |
| gptkbp:contraindication |
hypersensitivity to omalizumab
|
| gptkbp:dosage_form |
gptkb:software_framework
|
| gptkbp:formulation |
pre-filled syringe
|
| gptkbp:frequency |
every 2 to 4 weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xolair
|
| gptkbp:ingredients |
gptkb:omalizumab
|
| gptkbp:interacts_with |
none significant
|
| gptkbp:invention |
gptkb:2023
|
| gptkbp:is_monitored_by |
side effects
Ig E levels asthma control |
| gptkbp:is_used_for |
gptkb:asthma
chronic idiopathic urticaria |
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
long half-life
Ig E reduction |
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:price |
high
|
| gptkbp:provides_information_on |
recommended for chronic urticaria
recommended for severe asthma GINA guidelines NHLBI guidelines AAAAI guidelines |
| gptkbp:regulatory_compliance |
approved for adult use
approved for pediatric use |
| gptkbp:research |
effective in chronic spontaneous urticaria
effective in severe allergic asthma |
| gptkbp:research_areas |
immunology
allergy pulmonology |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
dizziness
fatigue headache nausea thromboembolic events injection site reactions anaphylaxis malignancy risk |
| gptkbp:storage |
refrigerated
|
| gptkbp:treatment |
improved quality of life
improved asthma control reduced exacerbations reduced use of rescue medication |